Tecan stock rises 4.68 percent near its yearly high

Tecan stock rose 4.68 percent to CHF 228 on the SIX Swiss Exchange on September 24, 2026, leaving the medical technology company CHF 0.60 below its 52-week high of CHF 228.60. The move places the shares at the upper edge of their annual range and gives the latest operating figures added market relevance.

First-half sales gain 3.4 percent

Group sales reached CHF 427.5 million in the first half of 2026, up 3.4 percent in local currencies but down 2.7 percent on a reported basis, according to Yahoo Finance. The contrast shows how currency effects continue to shape the headline growth rate.

The adjusted EBITDA margin stood at 15.1 percent for the same period, according to an announcement distributed through GlobeNewswire. For investors, the margin figure is the more important counterweight to the reported sales decline because it measures operating progress after currency translation.

Conference keeps margins central

Tecan announced on September 10, 2026, that CEO Monica Manotas would present at the Morgan Stanley Healthcare Conference on September 14, with the session focused on the company and its operating priorities, according to Tecan. The event connected the 15.1 percent adjusted EBITDA margin with the broader effort to improve profitability while maintaining growth in laboratory automation.

Tecan reported CHF 883 million in sales for fiscal year 2025, according to the same corporate announcement. That historical benchmark puts the CHF 427.5 million first-half 2026 result at 48.4 percent of the prior full-year figure, although the comparison covers different reporting periods.

Stock stays near yearly high

Tecan's market capitalization stood at CHF 2,885,544,744 on September 24, 2026, while trading volume reached 100,817 shares. The 52-week range was CHF 110.60 to CHF 228.60, making the latest price 106.3 percent above the annual low and 0.3 percent below the high.

The combination of a 4.68 percent daily gain, CHF 427.5 million in first-half sales and a 15.1 percent adjusted EBITDA margin gives the stock a clear data point for the current debate: growth is positive in local currencies, while reported revenue remains affected by exchange rates.